Adults with type 2 diabetes taking GLP-1 receptor agonists — medications that mimic a gut hormone to lower blood sugar, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — showed a 37% to 68% higher alopecia rate than patients on two other common diabetes drug classes, a Penn Medicine analysis of more than 50,000 records published in The BMJ on July 22, 2026 has found.

What did the comparison look like?

The team, led by Huilin Tang of the University of Pennsylvania, drew on Penn Medicine electronic health records covering adults treated between January 2019 and September 2024. The cohort ran two head-to-head analyses.

The first matched 12,004 GLP-1 users against 15,221 patients taking SGLT-2 inhibitors (sodium-glucose cotransporter-2 inhibitors, which lower blood sugar by spurring urinary glucose excretion). The second matched 11,964 GLP-1 users against 11,233 patients on DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors, oral drugs that boost insulin release).

GLP-1 patients were younger — mean age 58 versus 65 and 67 in the comparison cohorts — and carried higher body mass indexes of 36.2 versus 32.3 and 31.3.

How big was the gap?

After adjusting for age, sex, ethnicity, body mass index and pre-existing conditions, researchers logged 6.91 alopecia cases per 1,000 person-years (a measure that factors both patient count and time under observation) among GLP-1 users versus 5.04 among SGLT-2 patients. That is a 37% relative increase.

Against DPP-4 patients, the rate hit 6.53 versus 3.89 per 1,000 person-years, a 68% jump.

The signal concentrated in non-scarring alopecia, the form in which hair follicles stay intact and regrowth stays on the table. That subtype ran 53% higher versus SGLT-2 users and 72% higher versus DPP-4 users.

Why might GLP-1s trigger shedding?

The observational design — researchers tracked existing outcomes rather than assigning treatment — rules out a direct causal claim. The authors flag three candidate mechanisms:

• Rapid weight loss, a known trigger of telogen effluvium (a temporary surge in daily shedding that comes from follicles shifting into the resting phase of the hair growth cycle)
• Iron or zinc deficiencies that disrupt the growth cycle
• Hormonal shifts tied to weight change or to the drug itself

Any of these, alone or in combination, could explain the signal.

What didn't the study measure?

The team had no severity data, no duration data, and no way to confirm whether hair returned after patients stopped the medication. Confounding factors outside the records could also have skewed results.

The authors framed the finding as a clinical awareness flag rather than a contraindication: "Our findings extend previous anecdotal safety signals and provide more systematic evidence to inform clinical awareness of this potential adverse effect," they concluded.

What does this mean behind the chair?

For stylists and trichologists (scalp and hair-loss specialists), the absolute numbers matter more than the relative ones. Even at 6.91 cases per 1,000 person-years, fewer than one in 100 GLP-1 users developed alopecia in any given year of follow-up. The 37% and 68% headlines look large because the baseline risk starts small.

What's actionable: clients starting or escalating GLP-1 therapy can be briefed on the small but real risk of temporary shedding, and scalp health can be tracked through the early treatment months. Because the effect appears largely reversible, a proactive consult keeps the conversation grounded rather than alarming.

What's next?

The BMJ analysis is the most rigorous head-to-head alopecia comparison across diabetes drug classes to date. The unresolved questions — severity, duration, regrowth, mechanism — leave room for the next wave of research. For now, the data put hair loss on the GLP-1 watchlist, not in the contraindications column.